Vaxinnate: A Small NJ Biotech Company with a Huge Mission
April 21, 2011 Leave a comment
By Sara Lee Kessler
Vaxinnate, a nine-year-old New Jersey Biotech Company, has been awarded a 196-million-dollar federal contract to fund development of the next generation of flu vaccines. Instead of using hens’ eggs, which takes six months, Vaxinnate relies on recombinant technology, using ecoli bacteria as a platform. It’s much quicker.
Vodpod videos no longer available.